AIM ImmunoTech Inc. (AIM) Research

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

Market snapshot

Symbol
AIM
Price
$0.38
Day change
-5.03%
Market cap
$1.3M
P/E ratio
-0.12x
52-week range
0.21-19.73812
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Can-Fite BioPharma Ltd. (CANF)
  • Ensysce Biosciences, Inc. (ENSC)
  • KALA BIO, Inc. (KALA)
  • Pasithea Therapeutics Corp. (KTTA)
  • Oragenics, Inc. (OGEN)
  • Quoin Pharmaceuticals, Ltd. (QNRX)
  • Soligenix, Inc. (SNGX)
  • Alaunos Therapeutics, Inc. (TCRT)

Recent insider activity

  • Equels Thomas K — C-Conversion (25000 shares) on 2026-03-12
  • Equels Thomas K — C-Conversion (25 shares) on 2026-03-12
  • CHEMEROW DAVID I. — C-Conversion (25000 shares) on 2026-03-12
  • CHEMEROW DAVID I. — C-Conversion (25 shares) on 2026-03-12
  • Equels Thomas K — J-Other (50000 shares) on 2026-03-06

Open AIM ImmunoTech Inc. (AIM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.